Arcturus Therapeutics: Strategic Focus on Rare Diseases and Thermo Fisher Alliance Bring mRNA Specialists into Analyst Spotlight

Arcturus secures industry giant Thermo Fisher Scientific as a strategic partner for the phase 3 development and potential commercialization of the mRNA candidate ARCT-032. The analytics firm BTIG confirms a price target of $23 and evaluates progress on ARCT-810 as an important "Proof of Concept" for other liver-specific diseases. Freedom Broker has even initiated coverage on the stock with a "Buy" rating (price target $27). Experts emphasize the low short-term dilution risk for shareholders. Strategic repositioning in the mRNA sector Arcturus...